DK1220855T3 - Vandfri salte - Google Patents

Vandfri salte

Info

Publication number
DK1220855T3
DK1220855T3 DK00962772T DK00962772T DK1220855T3 DK 1220855 T3 DK1220855 T3 DK 1220855T3 DK 00962772 T DK00962772 T DK 00962772T DK 00962772 T DK00962772 T DK 00962772T DK 1220855 T3 DK1220855 T3 DK 1220855T3
Authority
DK
Denmark
Prior art keywords
pyridin
anhydrous salts
anhydrous
ylsulphonyl
ethylpiperazin
Prior art date
Application number
DK00962772T
Other languages
English (en)
Inventor
Michael Leslie Hughes
Richard Anthony Storey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1220855T3 publication Critical patent/DK1220855T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
DK00962772T 1999-10-11 2000-10-06 Vandfri salte DK1220855T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9923968.3A GB9923968D0 (en) 1999-10-11 1999-10-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
DK1220855T3 true DK1220855T3 (da) 2004-09-27

Family

ID=10862471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00962772T DK1220855T3 (da) 1999-10-11 2000-10-06 Vandfri salte

Country Status (17)

Country Link
EP (1) EP1220855B1 (da)
JP (1) JP2003511446A (da)
AT (1) ATE267203T1 (da)
AU (1) AU7441100A (da)
BR (1) BR0014656A (da)
CA (1) CA2382937A1 (da)
CO (1) CO5271692A1 (da)
DE (1) DE60010914T2 (da)
DK (1) DK1220855T3 (da)
ES (1) ES2219395T3 (da)
GB (1) GB9923968D0 (da)
PA (1) PA8503701A1 (da)
PE (1) PE20010674A1 (da)
PT (1) PT1220855E (da)
SV (1) SV2002000191A (da)
TN (1) TNSN00196A1 (da)
WO (1) WO2001027101A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158738A0 (en) * 2001-05-09 2004-05-12 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
GB0126417D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Crystal structure
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
WO2004097010A1 (en) * 2003-05-01 2004-11-11 Pfizer Limited Crystal of pde5, its crystal structure and its use in drug design

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723719B1 (en) * 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
CN1229349C (zh) * 1998-04-20 2005-11-30 美国辉瑞有限公司 吡啶－3－羧酸衍生物

Also Published As

Publication number Publication date
DE60010914D1 (de) 2004-06-24
WO2001027101A2 (en) 2001-04-19
EP1220855B1 (en) 2004-05-19
AU7441100A (en) 2001-04-23
PA8503701A1 (es) 2001-10-10
PT1220855E (pt) 2004-08-31
WO2001027101A3 (en) 2001-06-14
SV2002000191A (es) 2002-01-23
PE20010674A1 (es) 2001-06-27
EP1220855A2 (en) 2002-07-10
TNSN00196A1 (fr) 2005-11-10
ES2219395T3 (es) 2004-12-01
ATE267203T1 (de) 2004-06-15
DE60010914T2 (de) 2004-10-28
JP2003511446A (ja) 2003-03-25
CA2382937A1 (en) 2001-04-19
CO5271692A1 (es) 2003-04-30
BR0014656A (pt) 2002-06-11
GB9923968D0 (en) 1999-12-15

Similar Documents

Publication Publication Date Title
YU6303A (sh) Nova heterociklična jedinjenja, njihovo dobijanje i njihova upotreba kao medikamenata, a naročito kao anti-bakterijskih agenasa
DK0911333T3 (da) Pyrazol [4,3-d]pyrimidinderivater og farmaceutiske præparater, der indeholder disse
MXPA03011039A (es) Nuevos compuestos heterociclicos, su preparacion y uso como medicamentos, particularmente como agentes anti-bacterianos.
WO1999064409A3 (de) Benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
ATE316083T1 (de) Adamantanderivate
SE9904505D0 (sv) Novel compounds
ATE300541T1 (de) Pyrazolopyridinderivate
TW333527B (en) Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them
ATE376551T1 (de) Peptidborsäuren und deren verwendung in der herstellung von salzen derselben
GB0109122D0 (en) Novel compounds
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
CA2298461A1 (en) Heterocyclic substituted 4-benzoyl-pyrazole as herbicides
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
DK1220855T3 (da) Vandfri salte
EP0281943A3 (en) Substituted pyridine-2,4-carboxylic acid derivatives, process for their preparation, their use as well as medicaments based on these compounds
SE0102057D0 (sv) New Salts I
MY113529A (en) New derivatives of imidazole n- benzyldioxole,processes for their preparation, their use as medicaments and pharmaceutical compositions containing them
ATE62226T1 (de) Neue 3-pyridylmethylnaphthylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DK118988D0 (da) 1-(1-aryl-2-hydroxy-ethyl)-imidazoler og deres salte, deres fremstilling og anvendelse i laegemidler
EA200100157A3 (ru) Новые производные арил- или гетероарилхинолинилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции